● Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Condition: DLBCL · Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

PhasePhase 1/Phase 2

Planned participants37

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.

This description comes directly from the study's public registry record.

Talk to the study team

P.J. Lugtenburg, Dr. · +31 (0)10 7031672 · p.lugtenburg@erasmusmc.nl

M. Minnema, Prof. dr. · m.c.minnema@umcutrecht.nl

Always discuss trial participation with your own doctor first.

Locations (1)

NL-Rotterdam-ERASMUSMC

Rotterdam, Netherlands

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03356054